Literature DB >> 22308144

Interferon-based therapy for chronic hepatitis C: current and future perspectives.

Valli De Re.   

Abstract

Entities:  

Year:  2010        PMID： 22308144      PMCID： PMC3269089     

Source DB:  PubMed          Journal:  Hepat Mon        ISSN： 1735-143X            Impact factor:   0.660


× No keyword cloud information.
  11 in total

1.  Effects of interferon-alpha on peripheral neutrophil counts and serum granulocyte colony-stimulating factor levels in chronic hepatitis C patients.

Authors:  A Fukuda; H Kobayashi; K Teramura; S Yoshimoto; N Ohsawa
Journal:  Cytokines Cell Mol Ther       Date:  2000-09

2.  Pegylated interferon-alpha, ribavirin, and rituximab combined therapy of hepatitis C virus-related mixed cryoglobulinemia: a long-term study.

Authors:  Franco Dammacco; Felicia Anna Tucci; Gianfranco Lauletta; Pietro Gatti; Valli De Re; Vincenza Conteduca; Silvia Sansonno; Sabino Russi; Maria Addolorata Mariggiò; Maria Chironna; Domenico Sansonno
Journal:  Blood       Date:  2010-03-22       Impact factor: 22.113

3.  Characterization of resistance to the protease inhibitor boceprevir in hepatitis C virus-infected patients.

Authors:  Simone Susser; Christoph Welsch; Yalan Wang; Markus Zettler; Francisco S Domingues; Ursula Karey; Eric Hughes; Robert Ralston; Xiao Tong; Eva Herrmann; Stefan Zeuzem; Christoph Sarrazin
Journal:  Hepatology       Date:  2009-12       Impact factor: 17.425

4.  Combination treatment of advanced HCV associated liver disease with interferon and G-CSF.

Authors:  D H Van Thiel; H Faruki; L Friedlander; S Fagiuoli; P Caraceni; P J Molloy; R J Kania; H I Wright
Journal:  Hepatogastroenterology       Date:  1995 Nov-Dec

5.  Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection.

Authors:  John G McHutchison; Gregory T Everson; Stuart C Gordon; Ira M Jacobson; Mark Sulkowski; Robert Kauffman; Lindsay McNair; John Alam; Andrew J Muir
Journal:  N Engl J Med       Date:  2009-04-30       Impact factor: 91.245

6.  Antiviral effects and safety of telaprevir, peginterferon alfa-2a, and ribavirin for 28 days in hepatitis C patients.

Authors:  Eric Lawitz; Maribel Rodriguez-Torres; Andrew J Muir; Tara L Kieffer; Lindsay McNair; Ariya Khunvichai; John G McHutchison
Journal:  J Hepatol       Date:  2008-04-29       Impact factor: 25.083

7.  Telaprevir and pegylated interferon-alpha-2a inhibit wild-type and resistant genotype 1 hepatitis C virus replication in patients.

Authors:  Tara L Kieffer; Christoph Sarrazin; Janice S Miller; Martin W Welker; Nicole Forestier; Hendrik W Reesink; Ann D Kwong; Stefan Zeuzem
Journal:  Hepatology       Date:  2007-09       Impact factor: 17.425

8.  The comparative efficacy and safety of peginterferon alpha-2a vs. 2b for the treatment of chronic HCV infection: a meta-analysis.

Authors:  Seyed Moayed Alavian; Bita Behnava; Seyed Vahid Tabatabaei
Journal:  Hepat Mon       Date:  2010-06-01       Impact factor: 0.660

9.  Genetic variation in IL28B and spontaneous clearance of hepatitis C virus.

Authors:  David L Thomas; Chloe L Thio; Maureen P Martin; Ying Qi; Dongliang Ge; Colm O'Huigin; Judith Kidd; Kenneth Kidd; Salim I Khakoo; Graeme Alexander; James J Goedert; Gregory D Kirk; Sharyne M Donfield; Hugo R Rosen; Leslie H Tobler; Michael P Busch; John G McHutchison; David B Goldstein; Mary Carrington
Journal:  Nature       Date:  2009-10-08       Impact factor: 49.962

10.  Predictive values of amino acid sequences of the core and NS5A regions in antiviral therapy for hepatitis C: a Japanese multi-center study.

Authors:  Takeshi Okanoue; Yoshito Itoh; Hiroaki Hashimoto; Kohichiroh Yasui; Masahito Minami; Tetsuo Takehara; Eiji Tanaka; Morikazu Onji; Joji Toyota; Kazuaki Chayama; Kentaro Yoshioka; Namiki Izumi; Norio Akuta; Hiromitsu Kumada
Journal:  J Gastroenterol       Date:  2009-06-11       Impact factor: 7.527
View more
  2 in total

Review 1.  The advances in research on the pharmacological effects of Fructus Ligustri Lucidi.

Authors:  Zunting Pang; Zhou Zhi-yan; Wei Wang; Yanni Ma; Niu Feng-ju; Xuelan Zhang; Chunchao Han
Journal:  Biomed Res Int       Date:  2015-03-22       Impact factor: 3.411

2.  New globally faces of hepatitis B and C in the world.

Authors:  Seyed-Moayed Alavian
Journal:  Gastroenterol Hepatol Bed Bench       Date:  2011
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.